If you have been reading about weight loss medicine, two names come up more than any others: tirzepatide and semaglutide. They are often discussed as though they were the same thing. They are not. They work differently inside the body, they were studied differently, and in the one trial that compared them directly they produced different results.
This article explains the difference. It does not tell you which one is right for you, because that is not a question an article can answer. It is a question for a doctor who has examined you.
The short answer
Semaglutide copies one hormone. Tirzepatide copies two.
Both are given as a once weekly injection under the skin. Both act on the systems that govern appetite, fullness and how quickly the stomach empties. In the trial that put them head to head, tirzepatide produced a larger average reduction in body weight than semaglutide.
That last sentence is where most articles stop. It is also where the useful part begins, because a larger average result across a trial population is not the same as a better choice for an individual person.
What each one actually is
Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after you eat. It signals fullness to the brain, slows how fast the stomach empties, and forms part of the body’s natural appetite control. Semaglutide imitates that hormone, at a much steadier level than the body produces on its own.
Tirzepatide does the same thing, and one more thing. It is a dual agonist, meaning it acts on the GLP-1 receptor and also on the GIP receptor. GIP is a second gut hormone involved in appetite regulation and in how the body handles fat storage. The working theory, and it is still an area of active research rather than settled fact, is that acting on both pathways together produces a stronger effect than acting on one.
That is the whole structural difference between them. One pathway versus two.
The brand names, untangled
A great deal of confusion here comes from the fact that each molecule is sold under more than one brand name.
| Brand | Molecule | Licensed for |
| Wegovy | Semaglutide | Weight management |
| Zepbound | Tirzepatide | Weight management |
| Ozempic | Semaglutide | A different medical condition |
| Mounjaro | Tirzepatide | A different medical condition |
So Ozempic and Wegovy contain the same active molecule. Mounjaro and Zepbound contain the same active molecule. The brand names differ because the licence, the dosing and the intended use differ, not because the chemistry does.
When people say “I am on Ozempic” and mean weight loss, they are usually describing semaglutide. The distinction matters because the two licences are not interchangeable, and a doctor prescribes against a licence, not against a nickname.
What the head to head trial found
Most comparisons you will read online set trial results side by side that were never meant to be compared. Different trials enroll different people under different conditions, so a 20% result in one and a 15% result in another does not reliably mean the first medicine is better.
SURMOUNT-5 avoided that problem by testing both in the same trial.
It enrolled 751 adults with obesity and without the other condition either drug is also licensed for, and ran for 72 weeks. Each participant received the maximum dose they could tolerate: 10mg or 15mg weekly for tirzepatide, 1.7mg or 2.4mg weekly for semaglutide.
| Measure at 72 weeks | Tirzepatide | Semaglutide |
| Mean change in body weight | ~20.2% | ~13.7% |
| Mean weight change | ~22.8 kg | ~15.0 kg |
| Mean change in waist circumference | ~18.4 cm | ~13.0 cm |
| Stopped treatment due to gut side effects | 2.7% | 5.6% |
The difference in weight reduction was statistically significant. Tirzepatide participants were also more likely to reach each of the higher thresholds, such as losing at least 15% or at least 20% of body weight.
One detail from the trial that rarely gets repeated: weight reduction was about 6% lower in men than in women in both groups.
These are averages across a trial population, under trial conditions, with trial levels of monitoring and support. They are not a forecast of what any particular person will experience. Individual results in the trial ranged widely in both directions around those averages.
The wider evidence
SURMOUNT-1 studied tirzepatide against a placebo over 72 weeks in 2,539 adults. Mean weight reduction was 16.0% at 5mg, 21.4% at 10mg and 22.5% at 15mg, against 2.4% for placebo. Between 73% and 90% of participants on tirzepatide lost at least 10% of body weight, against 14% on placebo.
Semaglutide has a longer record in use and a deeper body of published evidence behind it, including large trials looking at outcomes beyond weight itself. For some patients that longer record carries real weight in a prescribing decision, which is one reason the medicine with the larger average number is not automatically the one a doctor reaches for.
Side effects
The side effect profile is broadly similar for both, and it is mostly gastrointestinal.
In SURMOUNT-1 the most common reported effects on tirzepatide were nausea (24.6% to 33.3% depending on dose, against 9.5% on placebo), diarrhoea (18.7% to 23.0%, against 7.3%) and vomiting (8.3% to 12.2%, against 1.7%). Most events were mild to moderate and clustered around the periods when the dose was being increased.
In the head to head trial, fewer people stopped tirzepatide because of gut side effects than stopped semaglutide, at 2.7% against 5.6%.
Both medicines carry contraindications and cautions that a doctor will assess against your own history before prescribing anything. Side effects, and what to do about them, are covered properly in a separate article written by a physician. Nothing here is a substitute for that conversation.
How they are taken
Both are once weekly injections given under the skin, and both are started low and increased slowly over a period of months rather than begun at full strength. That slow increase is deliberate. It is the main thing that makes the gut side effects manageable, and it is one of the reasons these medicines are prescribed with ongoing supervision rather than handed over once.
Dose decisions belong to the prescribing doctor. They depend on how you respond, what side effects you experience, and what else is going on in your health.
Why the bigger number is not automatically the better choice
This is the part most articles skip.
A doctor choosing between these two is not looking only at which produced more weight reduction in a trial. They are weighing your medical history and what else you are being treated for, how you tolerate the early doses, which product is actually available and supplied reliably where you live, what you can sustain over months rather than weeks, and what happens after, because stopping either medicine without a plan is its own subject.
Availability is a genuine factor in Jamaica and not a small one. A medicine that is theoretically more effective but inconsistently supplied is not more effective in practice.
For most people the honest answer is that both are serious medicines with real evidence behind them, and the right one is the one a doctor selects for your particular situation after an assessment. That assessment is the starting point of any medically supervised weight loss program, whoever provides it.
Frequently asked questions
Is tirzepatide just a stronger version of semaglutide? No. It is a different molecule that acts on two hormone pathways rather than one. It produced a larger average result in the head to head trial, but it is not the same drug at a higher dose.
Are Ozempic and Wegovy the same thing? They contain the same active molecule, semaglutide, but they are licensed differently and dosed differently. Only one of the two is licensed for weight management.
Can I switch from one to the other? That is a clinical decision and it is not something to attempt on your own. It involves restarting a dose escalation and it needs a doctor’s supervision.
How long do you stay on them? There is no single answer, and it is one of the most important questions to raise with a doctor before starting rather than after. Trial evidence on what happens after stopping is covered in a separate article.
Are these medicines available in Jamaica? Availability changes and depends on supply. A doctor is the right person to tell you what can actually be obtained and prescribed for you.
Can I buy either one without a prescription? No. Both are prescription medicines. Products offered for sale without a prescription, or compounded versions from unverified sources, carry real risks and are covered separately.
References
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025. doi:10.1056/NEJMoa2416394. PMID: 40353578. ClinicalTrials.gov: NCT05822830. Funded by Eli Lilly and Company, the manufacturer of tirzepatide.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID: 35658024. ClinicalTrials.gov: NCT04184622. Funded by Eli Lilly and Company, the manufacturer of tirzepatide.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. ClinicalTrials.gov: NCT03548935. Funded by Novo Nordisk, the manufacturer of semaglutide.
DISCLAIMER NOTICE
This article is general information about medicines and is not medical advice, a diagnosis, or a recommendation that any treatment is right for you. Whether any medicine is appropriate for you is decided by a registered physician after an assessment. Results vary between individuals.
Your consultation and any prescription are provided by an independent clinic registered with the Ministry of Health. EasyMeds is the platform that arranges and supports your care. EasyMeds does not provide medical care, diagnosis or treatment.